Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Alexis Borisy

- PMLiVE

Pfizer agrees pricing and distribution deal with US government

The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

- PMLiVE

Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

- PMLiVE

NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

Systemic mastocytosis affects approximately one in every 10,000 people in the UK

- PMLiVE

Roche’s Genentech and Blueprint receive full FDA approval for Gavreto in lung cancer

The targeted therapy was granted accelerated approval for the NSCLC indication in 2020

- PMLiVE

FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis

Ayvakit is now the first and only approved medicine designed to treat the underlying cause of the disease

Leaders in Pharma: Samir Vattompadam

In the inaugural episode of Impetus Digital's Leaders in Pharma podcast, I sit down with Samir Vattompadam. Samir is currently Vice President, Program Executive for EQRx.

Impetus Digital

- PMLiVE

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn

- PMLiVE

Lilly joins new Medicare scheme to reduce insulin prices

New model will cover seniors enrolled in Medicare Part D

- PMLiVE

FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging

Drug hit headlines after price jumped from $13.50 to $750 overnight

- PMLiVE

US start-up EQRx promises approach that will slash drug prices

Plans to have its first drug on the market in just five years

- PMLiVE

FDA clears Blueprint’s $32k-per-month GI cancer drug

First product approval for rare targeted therapy

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links